4-(哌啶-1-羰基)苯基硼酸 | 389621-83-4

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(哌啶-1-羰基)苯基硼酸
• 中文别名: 4-(哌啶-1-甲酰基)苯硼酸；4-(1-哌啶基羰基)苯硼酸
• 英文名称: (4-(piperidine-1-carbonyl)phenyl)boronic acid
• 英文别名: 4-(Piperidine-1-carbonyl)phenylboronic acid；[4-(piperidine-1-carbonyl)phenyl]boronic acid
• CAS: 389621-83-4
• 化学式: C₁₂H₁₆BNO₃
• mdl: MFCD03411951
• 分子量: 233.075
• InChiKey: PUXUKRSBJVVKMD-UHFFFAOYSA-N

物化性质

• 熔点：
  150-154°C
• 沸点：
  456.1±47.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.51
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  60.8
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P233,P260,P261,P264,P270,P271,P280,P301+P312,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P330,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-(哌啶-1-羰基)苯基硼酸 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 四丁基溴化铵 、 碳酸氢钠 、 sodium hydroxide 作用下， 以 乙二醇二甲醚 、 水 、 甲苯 为溶剂， 反应 8.0h， 生成 6-[4-(piperidine-1-carbonyl)phenyl]pyrrolo[2,3-b]pyridine-1-carboxylic acid 4-nitrophenyl ester
  参考文献：
  名称：

  7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors

  摘要：

  7-Azaindole-1-carboxamides were designed as a new class of PARP-1 inhibitors. The compounds displayed a variable pattern of target inhibition profile that, in part, paralleled the antiproliferative activity in cell lines characterized by homologous recombination defects. A selected compound (1l; ST7710AA1) showed significant in vitro target inhibition and capability to substantially bypass the multidrug resistance mediated by Pgp. In antitumor activity studies against the MX1 human breast carcinoma growth in nude mice, the compound exhibited an effect similar to that of Olaparib in terms of tumor volume inhibition when used at a lower dose than the reference compound. Treatment was well tolerated, as no deaths or significant weight losses were observed among the treated animals. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.12.031

文献信息

• 3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1
  作者：Fangrui Wu、Chao Zhou、Yuan Yao、Liping Wei、Zizhen Feng、Lisheng Deng、Yongcheng Song

  DOI：10.1021/acs.jmedchem.5b01361

  日期：2016.1.14

  overexpression. We report the design, synthesis, and structure–activity relationships of 3-(piperidin-4-ylmethoxy)pyridine containing compounds as potent LSD1 inhibitors with Ki values as low as 29 nM. These compounds exhibited high selectivity (>160×) against related monoamine oxidase A and B. Enzyme kinetics and docking studies suggested they are competitive inhibitors against a dimethylated H3K4 substrate

  组蛋白赖氨酸残基的甲基化在基因表达调节以及癌症起始中起重要作用。赖氨酸特异性脱甲基酶1（LSD1）负责维持组蛋白H3赖氨酸4（H3K4）的平衡甲基化水平。由于甲基化的H3K4或LSD1过表达的重要功能，LSD1是某些癌症的药物靶标。我们报告了作为有效LSD1抑制剂的含有3-（哌啶-4-基甲氧基）吡啶的化合物（与K i的设计，合成和结构-活性关系）值低至29 nM。这些化合物对相关的单胺氧化酶A和B表现出高选择性（> 160x）。酶动力学和对接研究表明它们是针对二甲基化H3K4底物的竞争性抑制剂，并提供了可能的结合方式。有效的LSD1抑制剂可以增加细胞H3K4甲基化并强烈抑制EC 50值低至280 nM的几种白血病和实体瘤细胞的增殖，而对正常细胞的作用却微不足道。
• [EN] NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES<br/>[FR] NOUVEAUX COMPOSÉS UTILES POUR LE TRAITEMENT DE MALADIES DÉGÉNÉRATIVES ET INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2010010189A1

  公开（公告）日：2010-01-28

  Novel [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a Formula represented by the Formula (I). These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotox in states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.

  揭示了具有由公式（I）表示的公式的新型[1,2,4]三唑并[1,5-a]吡啶化合物。这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如涉及软骨降解、骨骼和/或关节降解的疾病，例如骨关节炎；以及涉及炎症或免疫反应的疾病，如克罗恩病、类风湿性关节炎、牛皮癣、过敏性气道疾病（例如哮喘、鼻炎）、儿童特发性关节炎、结肠炎、炎性肠病、内毒素驱动的疾病状态（例如旁路手术后的并发症或慢性内毒素状态导致的慢性心力衰竭等），涉及软骨周转障碍的疾病（例如涉及软骨细胞合成刺激的疾病）、先天性软骨畸形、与IL6过度分泌和移植排斥（例如器官移植排斥）以及增生性疾病相关的疾病。
• Hydrogenation of (Hetero)aryl Boronate Esters with a Cyclic (Alkyl)(amino)carbene–Rhodium Complex: Direct Access to <i>cis</i> ‐Substituted Borylated Cycloalkanes and Saturated Heterocycles
  作者：Liang Ling、Yuan He、Xue Zhang、Meiming Luo、Xiaoming Zeng

  DOI：10.1002/anie.201811210

  日期：2019.5.13

  We herein report the hydrogenation of substituted aryl‐ and heteroaryl boronate esters for the selective synthesis of cis‐substituted borylated cycloalkanes and saturated heterocycles. A cyclic (alkyl)(amino)carbene‐ligated rhodium complex with two dimethyl groups at the ortho‐alkyl scaffold of the carbene showed high reactivity in promoting the hydrogenation, thereby enabling the hydrogenation of

  我们在此报告了取代的芳基和杂芳基硼酸酯的氢化反应，用于选择性合成顺式取代的硼化环烷烃和饱和杂环。在卡宾的邻烷基支架上带有两个二甲基的环状（烷基）（氨基）卡宾连接的铑配合物在促进氢化方面显示出高反应活性，从而使（杂）芳烃得以氢化并保留了合成有价值的硼酸酯团体。该过程构成了清洁，原子经济以及化学和立体选择性的途径，用于生成通常难以捉摸且难以制备的顺式构型，不同取代的硼酸化环烷烃和饱和杂环。
• Lipid probes and uses thereof
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US10168342B2

  公开（公告）日：2019-01-01

  Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.

  披露了用于识别脂质结合蛋白作为药物结合靶点的方法、组合物、探针、检测和试剂盒。此外，还披露了用于绘制脂质结合蛋白上的配体结合位点、识别脂质结合蛋白、生成药物-脂质结合蛋白轮廓、高通量药物筛选以及识别作为潜在脂质结合蛋白配体的药物的方法、组合物和探针。
• Novel Bisaryl Substituted Thiazoles and Oxazoles as Highly Potent and Selective Peroxisome Proliferator-Activated Receptor δ Agonists
  作者：Robert Epple、Christopher Cow、Yongping Xie、Mihai Azimioara、Ross Russo、Xing Wang、John Wityak、Donald S. Karanewsky、Tove Tuntland、Vân T. B. Nguyêñ-Trân、Cara Cuc Ngo、David Huang、Enrique Saez、Tracy Spalding、Andrea Gerken、Maya Iskandar、H. Martin Seidel、Shin-Shay Tian

  DOI：10.1021/jm9007399

  日期：2010.1.14

  The discovery, synthesis, and optimization of compound 1 from a high-throughput screening hit to highly potent and selective peroxisome proliferator-activated receptor δ (PPARδ) agonists are reported. The synthesis and structure−activity relationship in this series are described in detail. On the basis of a general schematic PPAR pharmacophore model, scaffold 1 was divided into headgroup, linker, and

  从高通量筛选到高效和选择性的过氧化物酶体增殖物激活受体δ（PPARδ）激动剂的发现，合成和优化了化合物1。详细介绍了该系列中的合成和构效关系。基于通用的PPAR药效团模型示意图，支架1将其分为头基，接头和尾基，并使用体外PPAR反式激活分析对PPAR激活进行了优化。有效和选择性的PPARδ活化需要一个（2-甲基苯氧基）乙酸头基，一个柔性连接基和一个带有两个疏水性芳基取代基的五元杂芳族中心环。这些芳基取代基的微调导致了一系列高效且选择性的化合物（例如化合物38c）在小鼠体内表现出出色的药代动力学特性。在体内急性给药模型中，该阵列的选定成员显示出可诱导丙酮酸脱氢酶激酶4（PDK4）和解偶联蛋白3（UCP3）的表达，这些基因已知参与能量稳态并受其调节。骨骼肌中的PPARδ。